Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models

被引:1
|
作者
Schlieper-Scherf, Steffen [1 ]
Hebach, Nils [2 ,3 ,4 ]
Hausmann, David [2 ,3 ,4 ]
Azorin, Daniel D. [2 ,3 ,4 ]
Hoffmann, Dirk C. [2 ,3 ,4 ]
Horschitz, Sandra [5 ,6 ]
Maier, Elena [1 ]
Koch, Phillip [5 ,6 ]
Karreman, Matthia A. [2 ,3 ,4 ]
Etminan, Nima [1 ]
Ratliff, Miriam [1 ,2 ]
机构
[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, Mannheim, Germany
[2] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Clin Cooperat Unit Neurooncol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany
[6] Hector Inst Translat Brain Res HITBR gGmbH, Mannheim, Germany
关键词
Glioma; Cancer neuroscience; Tumor microtubes; Cancer cell network; TTFields; ELECTRIC-FIELD; CELLS; RADIOTHERAPY; CANCER;
D O I
10.1007/s11060-024-04786-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study investigates the biological effect of Tumor Treating Fields (TTFields) on key drivers of glioblastoma's malignancy-tumor microtube (TM) formation-and on the function and overall integrity of the tumor cell network.MethodUsing a two-dimensional monoculture GB cell network model (2DTM) of primary glioblastoma cell (GBC) cultures (S24, BG5 or T269), we evaluated the effects of TTFields on cell density, interconnectivity and structural integrity of the tumor network. We also analyzed calcium (Ca2+) transient dynamics and network morphology, validating findings in patient-derived tumoroids and brain tumor organoids.ResultsIn the 2DTM assay, TTFields reduced cell density by 85-88% and disrupted network interconnectivity, particularly in cells with multiple TMs. A "crooked TM" phenotype emerged in 5-6% of treated cells, rarely seen in controls. Ca2+ transients were significantly compromised, with global Ca2+ activity reduced by 51-83%, active and periodic cells by over 50%, and intercellular co-activity by 52% in S24, and almost completely in BG5 GBCs. The effects were more pronounced at 200 kHz compared to a 50 kHz TTFields. Similar reductions in Ca2+ activity were observed in patient-derived tumoroids. In brain tumor organoids, TTFields significantly reduced tumor cell proliferation and infiltration.ConclusionOur comprehensive study provides new insights into the multiple effects of Inovitro-modeled TTFields on glioma progression, morphology and network dynamics in vitro. Future in vivo studies to verify our in vitro findings may provide the basis for a deeper understanding and optimization of TTFields as a therapeutic modality in the treatment of GB.
引用
收藏
页码:139 / 151
页数:13
相关论文
共 50 条
  • [31] LOCAL CONTROL AND RADIOLOGIC EFFECTS IN A GLIOBLASTOMA PATIENT TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) AND CHEMOTHERAPY
    Mergen, E.
    NEURO-ONCOLOGY, 2018, 20 : 234 - 234
  • [32] FIRST REPORT ON THE COMBINATION OF AXITINIB AND TUMOR TREATING FIELDS (TTFIELDS) IN THREE PATIENTS WITH RECURRENT GLIOBLASTOMA
    Kessler, A. F.
    Weiland, J.
    Linsenmann, T.
    Ernestus, R.
    Hagemann, C.
    Loehr, M.
    NEURO-ONCOLOGY, 2019, 21 : 73 - 73
  • [33] LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
    Rulseh, Aaron
    Derner, Adam
    Sroubek, Jan
    Klener, Jan
    Vymazal, Josef
    NEURO-ONCOLOGY, 2020, 22 : 58 - 59
  • [34] APPLYING TUMOR TREATING FIELDS (TTFIELDS) FOR ENHANCEMENT OF TEMOZOLOMIDE AND LOMUSTINE EFFICACY IN GLIOBLASTOMA CELL LINES
    Fishman, H.
    Monin, R.
    Dor-On, E.
    Kinzel, A.
    Haber, A.
    Giladi, M.
    Weinberg, U.
    Palti, Y.
    NEURO-ONCOLOGY, 2023, 25 : 63 - 63
  • [35] Optimized Methods to Quantify Tumor Treating Fields (TTFields)-Induced Permeabilization of Glioblastoma Cell Membranes
    Martinez-Paniagua, Melisa
    Khan, Sabbir
    Henning, Nikita W.
    Konagalla, Sri Vaishnavi
    Patel, Chirag B.
    METHODS AND PROTOCOLS, 2025, 8 (01)
  • [36] ADOPTING TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR GLIOBLASTOMA AND OTHER SOLID CANCERS: CHALLENGES AND OPPORTUNITIES
    Lustgarten, Leonardo
    Tatsui, Claudio
    Williams, Matthew
    Sengupta, Soma
    Wong, Eric
    NEURO-ONCOLOGY, 2023, 25
  • [37] Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields)
    Nickl, Vera
    Schulz, Ellina
    Salvador, Ellaine
    Trautmann, Laureen
    Diener, Leopold
    Kessler, Almuth F.
    Monoranu, Camelia M.
    Dehghani, Faramarz
    Ernestus, Ralf-Ingo
    Loehr, Mario
    Hagemann, Carsten
    CANCERS, 2022, 14 (21)
  • [38] Therapy with tumor treating fields (TTFields) and chemotherapy in a glioblastoma patient resulted in radiologic effects and local tumor control
    Mergen, E.
    Nolte, A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S67 - S67
  • [39] Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
    Davidi, Shiri
    Jacobovitch, Sara
    Shteingauz, Anna
    Martinez-Conde, Antonia
    Braten, Ori
    Tempel-Brami, Catherine
    Zeevi, Einav
    Frechtel-Gerzi, Roni
    Ene, Hila
    Dor-On, Eyal
    Voloshin, Tali
    Tzchori, Itai
    Haber, Adi
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    CANCERS, 2022, 14 (12)
  • [40] In vitro and in vivo evidence for the safety and efficacy of Tumor Treating Fields (TTFields) in combination with sorafenib
    Davidi, Shiri
    Tempel-Brami, Catherine
    Munster, Mijal
    Shteingauz, Anna
    Zeevi, Einav
    Schneiderman, Rosa
    Voloshin, Tali
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2020, 80 (16)